# A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

> **NCT02706951** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 648 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Upadacitinib
- **DRUG:** Placebo Upadacitinib
- **DRUG:** Placebo Methotrexate

## Key facts

- **NCT ID:** NCT02706951
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-23
- **Primary completion:** 2017-10-02
- **Final completion:** 2022-08-10
- **Target enrollment:** 648 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706951, "A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02706951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*